BJDX — Bluejay Diagnostics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1704287 ·
Last close
$0.90
Market Cap
$931.5K
52W High
$7.00
52W Low
$0.83
ADV30
5,018,945
Next earnings
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -1,938,831 -1,919,241 5,598,603 3,684,457 1,417,408
Dec 2025 0 -1,461,747 -1,429,812 7,119,237 5,164,875 1,143,948
Sep 2025 0 -1,616,947 -1,597,632 4,890,258 3,082,268 1,197,476
Jun 2025 0 -1,985,361 -1,956,604 6,403,258 4,443,076 1,113,027

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,457,918
Investing CF
$-189,049
Financing CF
$7,215,321
CapEx
$-20,114
Dividends Paid
Buybacks
EPS Diluted TTM
$-25.09
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-43,436,508
Inventory
Receivables
ST Investments
EBIT TTM
$-6,922,270
Pretax Income TTM
$-6,903,289
Interest Exp TTM
$1,338
Analysts

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -6,952,972 -6,848,483 7,119,237 1,143,948 -6,053,575
Dec 2024 0 -7,169,616 -7,717,794 6,657,423 927,924 -7,820,822
Dec 2023 0 -10,311,217 -9,953,888 4,868,531 1,973,683 -8,313,870
Dec 2022 249,040 -9,317,776 -9,296,948 13,521,265 1,979,992 -7,741,593
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.32

Peers — same industry

TickerNameMarket CapLastDaily %
ODYY Odyssey Health, Inc. $1.01M $0.01
LGMK LogicMark, Inc. $1.04M $1.16
VTAK Catheter Precision, Inc. $753.7K $0.21
PFSA Profusa, Inc. $1.16M $4.58
PREM Premier Air Charter Holdings Inc. $1.31M $0.04

News headlines (Yahoo Finance, 1h cache)

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
2026-08-13 10:00 · Yahoo
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
2026-07-21 10:30 · Yahoo
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-06-06 00:13 · Yahoo
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-02 16:19 · Yahoo
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
2026-06-02 10:30 · Yahoo
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
2026-05-07 20:01 · Yahoo
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
2026-04-07 10:30 · Yahoo
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
2026-03-12 10:30 · Yahoo
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
2026-03-11 13:29 · Yahoo
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
2026-03-06 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.